CombiGene will attend “Advanced Therapies Investor Day” in London

On the 9th of November, ARM (Alliance for Regenerative Medicine) together with Catapult (a British organisation for cell- and gene therapy) will organise an investor day in London to present interesting and innovative companies at research’s forefront.

Among those companies selected is CombiGene, which will be presented by the company’s chief executive, Jan Nilsson. The meeting is open for selected investors and the media.

CombiGene AB (publ)
Jan Nilsson, VD
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com